Agendia and Ferrer Enter Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
News Jul 16, 2008
Agendia BV and Ferrer inCode have announced an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services; MammaPrint®, a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint, a gene expression profiling service which offers a method of identifying the primary tumor site in Cancer of Unknown Primary (CUP).
Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain.
"We are confident that Ferrer inCode is the right partner for the successful expansion of MammaPrint and CupPrint into these additional European markets," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This agreement will allow us to increase the availability of our services to more customers in these countries, with the result being that more patients and their physicians will have access to the valuable information provided by these tests."
According to Agendia, the MammaPrint is a clinically proven, accurate gene expression profiling test that offers healthcare professionals a unique personalized prognostic analysis to determine a patient's individual risk of recurrence of breast cancer. CupPrint is a diagnostic service that identifies the origin of the primary tumor in Cancer of Unknown Primary, which accounts for up to five percent of all new cancer referrals and is the fourth most common cause of cancer mortality worldwide.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE